MiNK Therapeutics, Inc.

INKT · Nasdaq · United States

Share price · INKT

$8.84-3.16 (-26.33%) 3M

close as of 2026-11-18 · 24h delayed · vol 45K (3.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when INKT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 23 Oct 2026+6.5%
  2. 21 Oct 2026+7.7%
  3. 7 Jul 2026-8.1%
  4. 28 May 2026+19.8%
  5. 14 Apr 2026+16.9%

    Nothing announced by INKT that day or the session before.

  6. 27 Mar 2026+14.4%
  7. 11 Mar 2026-17.2%
  8. 10 Mar 2026+29.3%
  9. 6 Mar 2026-6.1%
  10. 5 Jan 2026+8.5%

Share of unusual movement by asset

For each asset, the share of INKT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Invariant TCR / NKG2D ligands (tumor cell recognition), no single defined myeloma antigenCell therapy
Multiple MyelomaGastric Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
agenT-797Phase 2Pneumonia
Est. primary completion 2027-06 · NCT07615010 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.2M$1.8M$7.5M$2.5M-$1.3M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$1.9M$8.8M$3.1M-$2.1M operating cash flowreport ↗
2026-Q1—$1.2M$9.5M$2.7M-$1.7M operating cash flowreport ↗
2025-Q3—$1.1M$14M$2.9M-$0.9M operating cash flowreport ↗
2025-Q2—$1.8M$1.7M$4.2M-$1.6M operating cash flowreport ↗
2025-Q1—$1.3M$3.2M$2.8M-$1.3M operating cash flowreport ↗
2024-Q3—$0.5M$6.3M$1.8M-$3.0M operating cash flowreport ↗
2024-Q2—$1.8M$9.3M$2.7M-$2.3M operating cash flowreport ↗
2024-Q1—$2.5M$5.8M$3.8M-$2.5M operating cash flowreport ↗
2023-Q3—$3.4M$6.4M$5.1M-$4.2M operating cash flowreport ↗
2023-Q2—$4.6M$11M$6.2M-$4.2M operating cash flowreport ↗
2023-Q1—$4.2M$15M$5.7M-$4.4M operating cash flowreport ↗
2022-Q3—$6.2M$24M$6.3M-$5.6M operating cash flowreport ↗
2022-Q2—$5.9M$30M$6.1M-$4.6M operating cash flowreport ↗
2022-Q1—$5.3M$35M$7.8M-$4.2M operating cash flowreport ↗
2021-Q3—$3.3M$0.8M$14M-$3.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$5.8M$13M$3.1M-$5.9M operating cash flowreport ↗

MiNK Therapeutics did not disclose revenue for 2025. R&D expense was $5.76M, down 9.1% YoY, and the company ended the year with cash and equivalents of $13.36M. Full-year net loss was $12.5M, or $2.93 per share, versus $10.8M in 2024, while the Q4 net loss was $2.6M, or $0.56 per share. The company noted it raised an additional $3.0M through its at-the-market program after year end, providing a runway through 2026.

Management expects to initiate the Phase 2 ARDS/hypoxemic pneumonia trial in 1H 2026, with early data by year-end, and anticipates first dosing in the GVHD Phase 1 trial in May 2026 with preliminary data in 2H 2026. Non-dilutive support includes the C-Further Consortium collaboration, an NIH NIAID STTR grant, and the Mary Gooze philanthropic award. Presentations at Keystone Symposia and SITC 2025 highlighted iNKT cell depletion in end-stage IPF and durable responses in checkpoint-resistant tumors. Leadership additions included Terese Hammond, John Holcomb, and Melissa Orilall.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$6.3M$4.6M$2.7M-$9.6M operating cash flowreport ↗
2023-FY—$15M$3.4M$5.6M-$16M operating cash flowreport ↗
2022-FY—$23M$20M$7.0M-$19M operating cash flowreport ↗
2021-FY—$14M$39M$7.5M-$13M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 9 sales ($120K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-12Buell Jennifer · director, Chief Executive OfficerOpen-market sale6,938$10.56$73KForm 4
2026-10-11Buell Jennifer · director, Chief Executive OfficerOption exercise23,191——Form 4
2026-10-11Buell Jennifer · director, Chief Executive OfficerOption exercise (derivative)23,191——Form 4
2026-09-01Corvese Brian · directorAward / grant1,633$10.95$18KForm 4
2026-09-01Ryan Barbara · directorAward / grant1,622$10.95$18KForm 4
2026-09-01Behner Peter · directorAward / grant1,485$10.95$16KForm 4
2026-09-01Holcomb John Bradley · directorAward / grant1,233$10.95$14KForm 4
2026-09-01WIINBERG ULF · directorAward / grant1,279$10.95$14KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 22 reporting institutions held 0.1M shares ($1.3M, 2.5% of shares outstanding).

#InstitutionSharesValue
1VANGUARD CAPITAL MANAGEMENT LLC59,364$625K
2GEODE CAPITAL MANAGEMENT, LLC17,345$183K
3Longbow Finance SA16,667$176K
4UBS Group AG15,202$160K
5VANGUARD FIDUCIARY TRUST CO8,287$87K
6BlackRock, Inc.6,203$65K
7Steward Partners Investment Advisory, LLC2,000$21K
8Annis Gardner Whiting Capital Advisors, LLC200$2K
9Tower Research Capital LLC (TRC)156$2K
10MORGAN STANLEY104$1K
11CITIGROUP INC91$958
12NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO18$190
13BNP PARIBAS FINANCIAL MARKETS16$168
14Game Plan Financial Advisors, LLC16$168
15Clearstead Advisors, LLC14$148